Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats

Lindsay R. Riddle, Rakesh Kumar, Suzy A. Griffin, Peter Grundt, Amy Hauck Newman, Robert R. Luedtke

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

The substituted 4-phenylpiperazine D3 dopamine receptor selective antagonist PG01037 ((E)-N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)but-2-enyl)- 4-(pyridin-2-yl)benzamide) was reported to attenuate l-dopa-associated abnormal involuntary movements (AIMs) in unilaterally lesioned rats, a model of l-dopa-dependent dyskinesia in patients with Parkinson's Disease (Kumar et al., 2009a). We now report that PG01042 (N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl) butyl)-4-(pyridin-3-yl)benzamide), which is a D3 dopamine receptor selective agonist for adenylyl cyclase inhibition and a partial agonist for mitogenesis, is also capable of attenuating AIMs scores. The intrinsic activity of PG01037 and PG01042 were determined using a) a forskolin-dependent adenylyl cyclase inhibition assay and b) an assay for agonist-associated mitogenesis. It was observed that the in vivo efficacy of PG01042 increased when administered by intraperitoneal (i.p.) injection simultaneously with l-dopa/benserazide (8 mg/kg each), as compared to a 60 min or 30 min pretreatment. PG01042 was found to attenuate AIM scores in these animals in a dose dependent manner. While PG01042 did not effectively inhibit SKF 81297-dependent AIMs, it inhibited apomorphine-dependent AIM scores. Rotarod studies indicate that PG01042 at a dose of 10 mg/kg did not adversely affect motor coordination of the unilaterally lesioned rats. Evaluation of lesioned rats using a cylinder test behavioral paradigm indicated that PG01042 did not dramatically attenuate the beneficial effects of l-dopa. These studies and previously published studies suggest that both D3 dopamine receptor selective antagonists, partial agonists and agonists, as defined by an adenylyl cyclase inhibition assay and a mitogenic assay, are pharmacotherapeutic candidates for the treatment of l-dopa-associated dyskinesia in patients with Parkinson's Disease.

Original languageEnglish
Pages (from-to)284-294
Number of pages11
JournalNeuropharmacology
Volume60
Issue number2-3
DOIs
StatePublished - Feb 2011

Keywords

  • D3 dopamine receptors
  • Dopamine receptors
  • Dyskinesia
  • Parkinson's Disease
  • l-dopa

Fingerprint Dive into the research topics of 'Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats'. Together they form a unique fingerprint.

  • Cite this